Clinical performance, intermediate and long-term outcomes of high-volume hemodiafiltration in patients with kidney failure

Semin Dial. 2022 Sep;35(5):420-426. doi: 10.1111/sdi.13105. Epub 2022 Jun 11.

Abstract

Hemodiafiltration (HDF), in which both convective and diffusion methods are combined, yields an increased overall solute clearance compared with hemodialysis (HD), specifically for medium and larger molecular weight uremic toxins. Due to uncertainty in the treatment effects, the nephrology community still perceives the implementation of HDF and the achievement of high convective volume as complex. In this article, we review practical aspects of the implementation of HDF that can effectively deliver a high-volume HDF therapy and assure clinical performance to most patients. We also present an overview of the impact of high-volume HDF (compared to HD) on a series of relevant biochemical, patient-reported, and clinical outcomes, including uremic toxin removal, phosphate, Inflammation and oxidative stress, hemodynamic stability, cardiac outcomes, nutritional effects, health-related quality of life, morbidity, and mortality.

Publication types

  • Review

MeSH terms

  • Hemodiafiltration* / adverse effects
  • Humans
  • Kidney Failure, Chronic* / etiology
  • Kidney Failure, Chronic* / therapy
  • Phosphates
  • Quality of Life
  • Renal Dialysis / methods
  • Renal Insufficiency*
  • Uremic Toxins

Substances

  • Phosphates
  • Uremic Toxins